New botulinum toxin approved with REMS.
Thompson
Cheryl A
CA
D001905:Botulinum Toxins / Q000009:adverse effects / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A; D017277:Drug Approval; D004348:Drug Labeling; D006801:Humans; D009465:Neuromuscular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018570:Risk Assessment / Q000379:methods; D012308:Risk Management / Q000379:methods; D014481:United States; D014486:United States Food and Drug Administration
D009465:Neuromuscular Agents; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A; C545476:incobotulinumtoxinA